Samsung Biologics Secures 87.9% Stake in Tender Offer for PolyPeptide
Samsung Biologics Co., Ltd. (KRX: 207940), operating through its subsidiary Samsung Peptide AG, secured 87.92% of the share capital and voting rights in Swiss contract manufacturer PolyPeptide Group AG (SIX: PPGN) following the end of its main tender offer period. Shareholders tendered 29,014,418 shares, fulfilling key conditions including the minimum acceptance rate and the absence of material adverse effects.
The successful tender offer allows Samsung Biologics to expand its global biomanufacturing capabilities into peptide drug manufacturing. Having passed the minimum ownership threshold, the South Korean company intends to perform a squeeze-out of remaining public investors and delist PolyPeptide from the SIX Swiss Exchange after closing.
Remaining shareholders can tender their shares during an additional acceptance period running from Oct. 19 to Oct. 30, 2026. PolyPeptide will host an extraordinary general meeting on Oct. 26, 2026, to vote on board appointments and governance updates. Pending regulatory approvals, transaction settlement is slated for late 2026 or early 2027.
Key points
- Samsung Biologics secured an 87.92% stake in PolyPeptide Group AG following the main public tender offer period.
- Key transaction conditions were satisfied, including minimum shareholder acceptance and material adverse effect terms.
- Shareholders who did not participate can tender shares during an additional acceptance period from Oct. 19 to Oct. 30, 2026.
- PolyPeptide scheduled an extraordinary general meeting for Oct. 26, 2026, to approve board changes and article amendments.
- Samsung Biologics plans to squeeze out minority holders and delist PolyPeptide following closing in late 2026 or Q1 2027.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What percentage of PolyPeptide did Samsung Biologics acquire?
Samsung Biologics and its subsidiary secured 87.92% of PolyPeptide Group AG share capital and voting rights, with 29,014,418 shares tendered during the main offer period.
When is the additional tender period for PolyPeptide shares?
The additional acceptance period opens on Oct. 19, 2026, and closes on Oct. 30, 2026, at 4:00 p.m. Swiss time.
Will PolyPeptide Group be delisted from the SIX Swiss Exchange?
Yes. Following transaction settlement, Samsung Biologics intends to initiate a squeeze-out of remaining public shareholders and apply for PolyPeptide shares to be delisted.